Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,323 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastrointestinal Anomalies Clear all
Completed Phase 3 Interventional Results available

A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

NCT03460990
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659/TEZ/IVA, TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
28
States / cities
Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation

NCT00909727
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Trikafta in Cystic Fibrosis Patients

NCT03506061
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Trikafta
Drug
Lead sponsor
Emory University
Other
Eligibility
12 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes

NCT02398383
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Interventions
Oral Glucose Tolerance Test, Mixed Meal Tolerance Test, Hypoglycemic Clamp
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

NCT02819856
View directory record Official record
Conditions
Ototoxicity
Interventions
Placebo, SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 15, 2026, 4:06 PM EDT
Recruiting Early Phase 1 Interventional

Personalized Theratyping Trial

NCT03587961
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Symdeko
Drug
Lead sponsor
George Solomon
Other
Eligibility
6 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Not applicable Interventional

Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis

NCT00850551
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Early Intervention
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

NCT04279769
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
CB-280, Placebos
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Little Rock, Arkansas • Long Beach, California • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 15, 2026, 4:06 PM EDT
Completed No phase listed Observational

Comparing Chest Images From MRI to CT in Patients With Cystic Fibrosis (CF)

NCT01860872
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 60 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 15, 2026, 4:06 PM EDT
Completed No phase listed Observational

Study of the Pathogenesis of Porphyria Cutanea Tarda

NCT00005103
View directory record Official record
Conditions
Porphyria Cutanea Tarda
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients

NCT00274313
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
552-02
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
14 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2009 · Synced Oct 15, 2026, 4:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nuclear Morphology of Breast Cells in Ductal Lavage

NCT00259597
View directory record Official record
Conditions
Benign Breast Disease
Interventions
breast ductal lavage
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Sorbent Therapy of the Cutaneous Porphyrias

NCT01422915
View directory record Official record
Conditions
Erythropoietic Protoporphyria
Interventions
Colestipol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
22 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 15, 2026, 4:06 PM EDT
Terminated No phase listed Observational

Diagnosis and Treatment of Patients With Cystic Fibrosis

NCT00001223
View directory record Official record
Conditions
Cystic Fibrosis, Liver Disease or Abnormalities, Diabetes, Pancreatic Insufficiency (Exocrine and Endocrine)
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years to 120 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 1 Interventional

ABT-751 in Treating Young Patients With Refractory Solid Tumors

NCT00036959
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ABT-751
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 15, 2026, 4:06 PM EDT
Recruiting Phase 1 Interventional

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

NCT06198296
View directory record Official record
Conditions
Hepatoblastoma, Hepatocellular Carcinoma, Wilms Tumor, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Rhabdomyosarcoma, Liposarcoma, Embryonal Sarcoma of Liver
Interventions
21.15.GPC3-CAR T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2043
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

NCT05104723
View directory record Official record
Conditions
Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease, Inflammatory Skin Disease, Inflammatory Lung Disease
Interventions
XELJANZ (tofacitinib)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 15, 2026, 4:06 PM EDT
Completed No phase listed Observational

Positional Cloning of the Gene(s) Responsible for Alagille Syndrome

NCT00001642
View directory record Official record
Conditions
Alagille Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 4:06 PM EDT
Recruiting No phase listed Observational

ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health

NCT07505797
View directory record Official record
Conditions
Breast Cancer, Benign Breast Condition, Breast Fibroadenoma, Breast Neoplasms, Breast Disease, Breast Cancer Female, Breast Pain, Breast Cancer Invasive, Breast Cancer Detection
Interventions
ATUSA 3D Automated Breast Ultrasound System
Device
Lead sponsor
iSono Health, Inc.
Industry
Eligibility
18 Years to 94 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Sacramento, California • Cypress, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 15, 2026, 4:06 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease

NCT00962260
View directory record Official record
Conditions
Gaucher Disease
Interventions
Plant cell expressed recombinant glucocerebrosidase (prGCD)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
U.S. locations
14
States / cities
La Jolla, California • Aurora, Colorado • Coral Springs, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

NCT01371825
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions
Sebelipase alfa (SBC-102)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 15, 2026, 4:06 PM EDT
Not listed Not applicable Interventional

A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis

NCT06350149
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sugar Sweetened Beverages (SSB), Hi GI, Lo GI
Other
Lead sponsor
Emory University
Other
Eligibility
12 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 15, 2026, 4:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, Metastatic Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Acinar Cell Carcinoma
Interventions
ART0380, Gemcitabine, Irinotecan
Drug
Lead sponsor
Artios Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 15, 2026, 4:06 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease

NCT00322868
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
pioglitazone
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 15, 2026, 4:06 PM EDT